Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects with Relapsed or Refractory Aggressive B-Cell Malignancies

This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.

开始日期2023-05-09

申办/合作机构

Oncternal Therapeutics, Inc.

100 项与 ROR1 CAR-T (Oncternal Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 ROR1 CAR-T (Oncternal Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 ROR1 CAR-T (Oncternal Therapeutics) 相关的专利（医药）

登录后查看更多信息

项与 ROR1 CAR-T (Oncternal Therapeutics) 相关的文献（医药）

2024-04-01·Journal for immunotherapy of cancer

Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1

Article

作者: Chand Thakuri, Bal Krishna ; Tran, Ngoc Q ; Dash, Pradyot ; Schneider, Dina ; Lee, Jia-Jye ; Hu, Peirong ; Steimle, Brittany ; Tran, Tri Minh ; Nurmukhambetova, Saule

Background:

Chimeric antigen receptor (CAR) T-cell therapy target receptor tyrosine kinase-like orphan receptor 1 (ROR1) is broadly expressed in hematologic and solid tumors, however clinically-characterized ROR1-CAR T cells with single chain variable fragment (scFv)-R12 targeting domain failed to induce durable remissions, in part due to the immunosuppressive tumor microenvironment (TME). Herein, we describe the development of an improved ROR1-CAR with a novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, transforming growth factor beta (TGFβ).

Methods:

CAR T cells were generated by lentiviral transduction of enriched CD4+and CD8+T cells, and the novel scFv9-based ROR1-CAR-1 was compared with the clinically-characterized ROR1-R12-scFv-based CAR-2 in vitro and in vivo.

Results:

CAR-1 T cells exhibited greater CAR surface density than CAR-2 when normalized for %CAR+, and produced more interferon (IFN)-γ tumor necrosis factor (TNF)-α and interleukin (IL)-2 in response to hematologic (Jeko-1, RPMI-8226) and solid (OVCAR-3, Capan-2, NCI-H226) tumor cell lines in vitro. In vivo, CAR-1 and CAR-2 both cleared hematologic Jeko-1 lymphoma xenografts, however only CAR-1 fully rejected ovarian solid OVCAR-3 tumors, concordantly with greater expansion of CD8+and CD4+CAR T cells, and enrichment for central and effector memory phenotype. When equipped with TGFβ-protective armor TGFβRIIDN, CAR-1 T cells resisted TGFβ-mediated pSmad2/3 phosphorylation, as compared with CAR-1 alone. When co-cultured with ROR-1+AsPC-1 pancreatic cancer line in the presence of TGFβ1, armored CAR-1 demonstrated improved recovery of killing function, IFN-γ, TNF-α and IL-2 secretion. In mouse AsPC-1 pancreatic tumor xenografts overexpressing TGFβ1, armored CAR-1, in contrast to CAR-1 alone, achieved complete tumor remissions, and yielded accelerated expansion of CAR+T cells, diminished circulating active TGFβ1, and no apparent toxicity or weight loss. Unexpectedly, in AsPC-1 xenografts without TGFβ overexpression, TGFβ1 production was specifically induced by ROR-1-CAR T cells interaction with ROR-1 positive tumor cells, and the TGFβRIIDN armor conferred accelerated tumor clearance.

Conclusions:

The novel fully human TGFßRIIDN-armored ROR1-CAR-1 T cells are highly potent against ROR1-positive tumors, and withstand the inhibitory effects of TGFß in solid TME. Moreover, TGFβ1 induction represents a novel, CAR-induced checkpoint in the solid TME, which can be circumvented by co-expressing the TGβRIIDN armor on T cells.

2022-12-01·Breast cancer research : BCR

Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC

Article

作者: Muczynski, Vincent ; Della Peruta, Marco ; Nathwani, Amit Chunilal ; Patel, Dominic ; Lau, Hiu ; Miranda, Elena ; Gohil, Satyen Harish ; Evans, Rachel ; Harrasser, Micaela ; Granger, David ; Grigoriadis, Kristiana ; Grigoriadis, Anita

Abstract:

Background:

Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosuppressive tumor microenvironment (TME) which limits the activity of tumor-infiltrating lymphocytes (TILs) including CAR-T cells. We have developed a next-generation armored CAR (F i-CAR) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is expressed at high levels in a range of aggressive tumors including poorly prognostic triple-negative breast cancer (TNBC). The F i-CAR-T is designed to release an anti-PD-1 checkpoint inhibitor upon CAR-T cell activation within the TME, facilitating activation of CAR-T cells and TILs while limiting toxicity.

Methods:

To bolster potency, we developed a F i-CAR construct capable of IL-2-mediated, NFAT-induced secretion of anti-PD-1 single-chain variable fragments (scFv) within the tumor microenvironment, following ROR1-mediated activation. Cytotoxic responses against TNBC cell lines as well as levels and binding functionality of released payload were analyzed in vitro by ELISA and flow cytometry. In vivo assessment of potency of F i-CAR-T cells was performed in a TNBC NSG mouse model.

Results:

F i-CAR-T cells released measurable levels of anti-PD-1 payload with 5 h of binding to ROR1 on tumor and enhanced the cytotoxic effects at challenging 1:10 E:T ratios. Treatment of established PDL1 + TNBC xenograft model with F i-CAR-T cells resulted in significant abrogation in tumor growth and improved survival of mice (71 days), compared to non-armored CAR cells targeting ROR1 (F CAR-T) alone (49 days) or in combination with systemically administered anti-PD-1 antibody (57 days). Crucially, a threefold increase in tumor-infiltrating T cells was observed with F i-CAR-T cells and was associated with increased expression of genes related to cytotoxicity, migration and proliferation.

Conclusions:

Our next-generation of ROR1-targeting inducible armored CAR platform enables the release of an immune stimulating payload only in the presence of target tumor cells, enhancing the therapeutic activity of the CAR-T cells. This technology provided a significant survival advantage in TNBC xenograft models. This coupled with its potential safety attributes merits further clinical evaluation of this approach in TNBC patients.

2021-02-01·Cancer cell1区 · 医学

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade

1区 · 医学

Article

作者: Sarah M. Garrison ; Valentin Voillet ; Christoph Rader ; Sushma Yechan-Gunja ; Robert H. Pierce ; Smitha P.S. Pillai ; Vishaka Muhunthan ; Jennifer M. Specht ; A. McGarry Houghton ; Kimberly S. Smythe ; Carolina Berger ; Robert A. Amezquita ; David G. Maloney ; Megha Sarvothama ; Scott N. Furlan ; Carla A. Jaeger-Ruckstuhl ; Shivani Srivastava ; Raphael Gottardo ; Stanley R. Riddell ; Sylvia M. Lee

Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast and lung cancer patients, CAR-T cells targeting the tumor-associated antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1) infiltrate tumors poorly and become dysfunctional. To test strategies for enhancing efficacy, we adapted the Kras^LSL-G12D/+;p53^f/f autochthonous model of lung adenocarcinoma to express the CAR target ROR1. Murine ROR1 CAR-T cells transferred after lymphodepletion with cyclophosphamide (Cy) transiently control tumor growth but infiltrate tumors poorly and lose function, similar to what is seen in patients. Adding oxaliplatin (Ox) to the lymphodepletion regimen activates tumor macrophages to express T-cell-recruiting chemokines, resulting in improved CAR-T cell infiltration, remodeling of the tumor microenvironment, and increased tumor sensitivity to anti-PD-L1. Combination therapy with Ox/Cy and anti-PD-L1 synergistically improves CAR-T cell-mediated tumor control and survival, providing a strategy to improve CAR-T cell efficacy in the clinic.

项与 ROR1 CAR-T (Oncternal Therapeutics) 相关的新闻（医药）

2024-10-28

·佰傲谷BioValley

核心管线挣扎无效，不详的ROR1

ROR1 CAR-T细胞疗法LYL797，在报告了临床死亡事件后，研发公司Lyell Immunopharma努力挣扎了4个月后，最终还是宣布停止对其的开发。又一领先的ROR1 CAR-T管线停止，预示着ROR1靶点的不详。患者死亡事件 2024年6月，Lyell报告了LYL797在三阴乳腺癌（TNBC）的I期临床中发生了一例死亡事件。延伸阅读：实体瘤CAR-T患者死亡，股价跌去36% LYL797是一款基于Lyell公司专有的Gen-R技术平台开发的ROR1靶向CAR-T细胞，经过体外重编程使T细胞过表达蛋白质c-JUN，从而实现延缓衰竭并保持抗肿瘤功能。在一项针对三阴乳腺癌的I期临床中，一名患者在第41天出现5级呼吸衰竭后死亡。此外，22%的患者中出现肺炎相关的剂量限制毒性，最常见的严重程度为3级或更高。出现死亡事件的可能原因是ROR1靶点。虽然ROR1在正常的肺部细胞中几乎不表达，但是在一些肺癌中呈现出异常高表达，而考虑到乳腺癌的特殊位置，一些患者实际上已经出现了乳腺癌的肺转移情况，这也使得一些患者出现肺部受累的情况。 LYL797挣扎无效实际上，LYL797的这例死亡事件并没有引起美国FDA的警惕，临床并未暂停。Lyell公司仅是对临床进行了调整。 Lyell公司在2024年8月发布的第二季度财报中，还报告了LYL797的临床开发计划，包括针对三阴性乳腺癌（TNBC）或非小细胞肺癌（NSCLC）的临床继续进行，扩大标签至卵巢癌和子宫内膜癌，以及下半年提交针对多发性骨髓瘤和慢性淋巴细胞白血病的第二个IND。很明显，死亡事件一开始并未打击到Lyell公司对于LYL797的信心。同时，该公司以TNBC研究的最高剂量队列中，40%的客观缓解率和60%的临床获益率，作为宣传的主要数据。然后，期间不知道发生了什么，在距第二季度财报发布2个月多后，Lyell公司突然宣布要停止对LYL797的开发工作。 Lyell公司的首席执行官Lynn Seely在电话会议上，表明LYL797遇到了安全问题，并且没有“足够广泛的治疗窗口”。另外，同时被放弃的还包括LYL845在内的TIL项目，停止LYL845的原因很明确，因为临床数据不符合持续开发的预期标准，导致其他TIL项目也一同被放弃了。仍然死磕ROR1 小编猜测，LYL797的安全问题主要还是归因于，ROR1靶点比较难把控。无独有偶，另一家ROR1开发公司Oncternal也报告了ROR1 CAR-T（ONCT-808）临床发生了死亡案例，同时预期ONCT-808治疗会发生不良事件。ONCT-808的临床已经停止，同时该公司现在正在考虑战略代替方案....... 延伸阅读： 2个核心管线同时暴雷，首席医疗官出走 ROR1 CAR-T：临床数据出炉但是，ROR1开发难度高也不好使。在LYL797失败后，Lyell公司仍然在死磕ROR1 CAR-T。因为Lyell公司在管线重组以后，新的核心管线赫然是以LYL797为基础开发的下一代的ROR1 CAR-T疗法LYL119。Lyell公司表示，LYL119能够在更低剂量下产生更好的疗效，并具有更广泛的治疗窗口。 ROR1 CAR-T的下一代产品LYL119在c-JUN过表达的基础上还增添了多项技术，例如敲除NR4A3基因进一步减少T细胞凋亡和衰竭，采用Stim-R™技术来强化信号转导，采用该公司的Epi-R™技术生产具有持久干细胞特性的T细胞。最后在本身的技术之外，还结合了来自哈佛大学Wyss研究所的T细胞增强支架技术来强化临床获益，这种技术提供了一种能够模拟人体淋巴系统的支架材料，这种支架材料可以携带激活CAR-T需要的IL-2以及CAR-T上的CD3受体和CD28受体。目前，该公司已经完成了LYL119的IND提交，预计将于今年或明年初启动针对铂类耐药卵巢癌或复发/难治性子宫内膜癌的1期临床。 CD19/CD20 CAR-T也挺香另一个好消息是，Lyell公司也没有头铁到眼里只有ROR1。在自身管线或是因为安全性、或是因为疗效被放弃，只剩下一根独苗LYL119后，Lyell公司将目光放到了外部，瞄准了一家小型CAR-T研发公司ImmPACT Bio，并以3000万美元现金和3750万股Lyell普通股对ImmPACT Bio进行收购。被Lyell公司看中的是ImmPACT管线内一款CD19/CD20 CAR-T细胞候选产品IMPT-314。ImmPACT的其他管线（包括Claudin 18.2 CAR-T）优先级并不高。 IMPT-314是一款自体的、CD19/CD20双特异性CAR-T细胞，被开发用于治疗B细胞淋巴瘤和自身免疫性疾病。Lyell公司将优先开发IMPT-314的B细胞淋巴瘤适应症。 IMPT-314目前正在进行临床研究，预计将于今年晚些时候发布IMPT-314针对大B细胞淋巴瘤的临床数据。IMPT-314的关键试验预计将于2025年启动。根据Lyell公司第二季度财报，截止2024年6月30日，拥有现金、现金等价物和有价证券4.911亿美元。尽管收购ImmPACT需要花费一定现金，但是Lyell公司删减了管线的开发工作，仅剩2条临床管线，这使得Lyell公司的现金流支持公司运营至2027年。小结虽然但是，Lyell公司一口气停了好几个内部管线的开发，包括LYL797和全部的TIL项目，还是令人对其的研发实力产生质疑。这一点也反应到了股市上，Lyell公司的股票持续下跌，截止本文发布前，已经跌至1美元以下，报9.27美分/股。参考资料： 1.https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-acquire-immpact-bio-and-prioritizes-its 2.https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-reports-business-highlights-and-financial-5 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

免疫疗法财报临床1期细胞疗法临床申请

2024-10-25

·GlobeNewswire-Health Care

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oct. 22, 2024 -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based on initial pharmacokinetic results, two additional dosing cohorts with twice daily (BID) oral dosing of ONCT-534 had been incorporated in the Phase 1/2 study ONCT-534-101 (NCT05917470). Overall, fifteen patients received ONCT-534 once daily (QD) in six dosing cohorts and six patients received ONCT-534 BID in two dosing cohorts. Based on a data cut off of September 30, 2024, the BID dosing schedule was well tolerated, with no related Grade 3 or higher toxicities. One patient, who experienced a rising PSA on ONCT-534 at 160 mg BID, had a subsequent 50% reduction in PSA after four weeks of ONCT-534 at 300 mg BID, and at the same time the CAT Scan showed a 16% reduction in target lesions compared to baseline. Enumeration and biomarker analysis of circulating tumor cells (CTCs) showed promising effects on expression of androgen receptor (AR)-regulated genes, and AR nuclear translocation in six additional patients. CTC analysis also showed that some patients who did not respond to ONCT-534 had prostate cancer that had developed neuroendocrine features, which are associated with AR independent disease. “While we still believe the decision to discontinue the ONCT-534-101 clinical trial remains the correct one in the current biotechnology environment, the updated clinical results highlight the potential of ONCT-534 in prostate cancer. We believe there is value in exploring BID dosing further, as well as studying ONCT-534 in earlier lines of therapy for advanced prostate cancer,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We continue to explore strategic alternatives for our product candidates, including ONCT-534, ONCT-808, zilovertamab and ONCT-216 in an ongoing effort to maximize value to our shareholders.” Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. More information on our company and programs is available at https://oncternal.com/. ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) with demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR mutation and aberration. It is a potential treatment for patients with mCRPC with unmet medical need because of resistance to androgen receptor pathway inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. It was investigated in Study ONCT-534-101 (NCT05917470) for the treatment of patients with mCRPC who are resistant to current AR pathway inhibitors. ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced compared with currently approved CAR T products. It was investigated in Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment. Zilovertamab (previously called cirmtuzumab and UC-961) is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which resulted in 100% progression free survival (PFS) at 48 months in CLL patients whose tumors harbored del(17p)/p53 mutation, a population underserved by current treatment options. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to zilovertamab for the treatment of CLL and MCL. The results of an investigator-sponsored, Phase 1b clinical trial of zilovertamab in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer were recently published (Shatsky 2023). Zilovertamab was evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (NCT05156905), and an investigator-initiated Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory (R/R) CLL (NCT04501939). ONCT-216 (previously called TK216) is an investigational targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins including fusion proteins. Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in most cases of Ewing sarcoma. ETS-related translocations or overexpression are also found in many other tumors such as acute myeloid leukemia (AML), diffuse large B cell lymphoma (DLBCL), and prostate cancer. In preclinical models, ONCT-216 was observed to bind to EWS-FLI1, blocking the interaction between this fusion protein and other transcriptome proteins such as RNA helicase A, leading to tumor cell apoptosis and inhibiting tumor growth in animal models. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Status to ONCT-216 for the treatment of Ewing sarcoma. The results of a Phase 1/ 2 clinical trial of ONCT-216 in patients with Ewing sarcoma (NCT02657005) were recently published (Myers 2024). The content above comes from the network. if any infringement, please contact us to modify.

临床结果孤儿药快速通道免疫疗法

2024-09-14

·药渡

2个核心管线同时暴雷，首席医疗官出走

一个候选药物失败，还能说是小问题。两个核心产品同时出问题，这对于一家Biotech来说，无疑是致命的。 Oncternal Therapeutics的两款临床候选药物ONCT-534（双效雄激素受体抑制剂）和ONCT-808（自体ROR1 CAR-T），分别因疗效和毒性问题停止了临床试验。同日（2024年9月12日），该公司宣布将考虑战略代替方案，裁员37%。以及首席医疗官也出走了。核心管线同时暴雷 Oncternal公司有4条管线，分别是ONCT-534（双效雄激素受体抑制剂）、ONCT-808（自体ROR1 CAR-T）、Zilovertamab（ROR1单抗，被取消了优先级）、以及一款被取消优先级的早期管线ONCT-216。 Oncternal管线（图片来源：参考资料2）其中，ONCT-534和ONCT-808同时爆雷，停止临床研究。 ONCT-534是一种新型、口服的双效雄激素受体抑制剂，被开发用于治疗转移性去势抵抗性前列腺癌（mCRPC）。 ONCT-534的1期试验中期结果显示：8个给药队列中的20名患者未能显示出疾病改善，包括前列腺特异性抗原（PSA）水平。ONCT-534通常耐受性良好，在最高剂量队列中，3名患者中有2名观察到剂量限制性毒性。 ONCT-808是一款自体的ROR1 CAR-T细胞治疗，也是全球进度最快的ROR1 CAR-T项目之一。被开发用于治疗复发/难治性（R/R）侵袭性B细胞恶性肿瘤。 ONCT-808的更新数据显示：在每个剂量中都表现出具有抗肿瘤活性，包括持续8个月的完全代谢反应和CAR-T细胞的长期持久性。但是CAR-T治疗预期会出现不良事件，以及在最高剂量队列中经历了因休克并发症导致的死亡事件。 Oncternal公司表示，根据现有的临床数据和持续开发的资金要求，决定终止研究。放弃治疗在同一份新闻稿中，Oncternal公司表示将专注于探索战略代替方案，以实现股东价值最大化的目标，其中可能包括资产出售、许可，或公司并购、反向并购以及其他业务合并。在这项战略探索进行期间，Oncternal将停止所有产品的研发活动，同时采取其他措施来降低运营成本，包括裁员。但实际上，两款临床管线的暴雷原本还不完全致命。因为Oncternal公司还拥有一款后期阶段的管线Zilovertamab。Zilovertamab是全球首个进入3期临床的ROR1单抗。 Zilovertamab的疗效数据看起来还不错。在与ibrutinib联用的1/2期临床中，表达P53突变/del(17p)的CLL患者获得100%的无进展生存期（PFS），持续48个月。但是在2023年4月，Oncternal公司取消了Zilovertamab的优先级，关闭了其针对MCL的3期研究和1/2期研究。小编未能找到Oncternal降低Zilovertamab优先级的披露原因，部分原因推测为没有足够的资金。放弃了在全球范围来说都是最领先的管线，后提上的两个管线又一起暴雷，再加上公司紧张的现金流...... Oncternal公司决定放弃治疗。小结从Oncternal公司目前的情况来看，可能资产并不怎么值钱了。两款核心管线都出事，不是没效，就是毒性大，这很难不嘀咕Oncternal的研发能力和技术水平。 Oncternal公司的倒下，同时也为ROR1靶向治疗的开发增加了一丝阴霾....... 参考资料： 1.https://investor.oncternal.com/news-releases/news-release-details/oncternal-therapeutics-announces-termination-its-clinical 2.https://www.oncternal.com/pipeline/overview/ 3.https://investor.oncternal.com/static-files/fb10e230-e261-45c2-be43-90a980dd8d81 4.https://www.biospace.com/job-trends/oncternal-to-lay-off-37-of-employees-including-cmo 药渡媒体商务合作媒体公关 | 新闻&会议发稿张经理：18600036371（微信同号）点击下方“药渡“，关注更多精彩内容免责声明 “药渡”公众号所转载该篇文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请及时告知，我们会在24小时内删除相关信息。微信公众号的推送规则又双叒叕改啦，如果您不点个“在看”或者没设为"星标"，我们可能就消散在茫茫文海之中~点这里，千万不要错过药渡的最新消息哦！👇👇👇

免疫疗法细胞疗法并购临床3期临床结果

100 项与 ROR1 CAR-T (Oncternal Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
B细胞恶性肿瘤	临床2期	美国	Oncternal Therapeutics, Inc.	2023-05-09
非霍奇金淋巴瘤	临床2期	美国	Oncternal Therapeutics, Inc.	2022-10-05
血液肿瘤	临床前	-	Oncternal Therapeutics, Inc.	-
实体瘤	临床前	-	Oncternal Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05588440 (ONCT-808-101, Corporate Publications) 人工标引	临床1/2期	侵袭性 B 细胞非霍奇金淋巴瘤	3	ONCT-808	遞窪鑰餘築簾獵襯鹹餘(蓋製糧壓鬱繭廠顧鏇鹽) = included decreased blood counts, pneumonia and Grade 1-2 cytokine release syndrome (CRS) as of a 4 December 2023 data cutoff 鬱簾鹹憲簾齋窪鹹齋餘 (鬱廠鑰鑰選夢蓋獵醖鏇 )	积极	2023-12-26
SITC2023	N/A	ROR1	-	ONCT-808	憲願窪衊糧餘廠遞網鑰(齋窪憲廠艱淵艱鏇膚鬱) = 簾鏇範蓋夢鏇鹹選觸淵製獵壓願艱網窪餘齋顧 (醖築選衊積觸遞觸獵蓋 )	积极	2023-11-02